Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...
Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...
Barchart on MSN
Here's what to expect from Bio-Techne's next earnings report
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science ...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...
Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S. equity ...
MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate ...
In an effort to boost production of materials used in cell and gene therapy, Minneapolis-based life sciences company Bio-Techne Corp. is spending up to $50 million to create a new manufacturing ...
Bio-Techne Corporation TECH is set to release its first-quarter fiscal 2025 results on Oct. 30, before the opening bell. The medical diagnostic testing provider posted adjusted earnings per share (EPS ...
Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback